ATP Synthase Agonist

PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984)-based Gefitinib (HY-50895) EGFR PROTAC degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC).

Aloracetam is a γ-aminobutyric acid cyclic derivative that can pass through the blood-brain barrier and has a significant enhancing cognitive function effect. Aloracetam improves the blood perfusion of brain tissue, increases the synthesis of proteins, ATP and acetylcholine in the brain, enhances the excitatory conduction effect of cholinergic nerves, and reduces the damage to brain tissue caused by cerebral vascular diseases. Aloracetam also has certain anti-epileptic, anti-inflammatory, analgesic and anti-depressant effects.